Geneuro

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of disability caused by autoimmune diseases, starting with Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). By leveraging insights into Human Endogenous Retroviruses (HERVs), which account for over 8% of human DNA and may contribute to autoimmune conditions, GeNeuro is advancing temelimab, a monoclonal antibody targeting HERV-W Env, a HERV protein found in the brain of MS patients. Temelimab has shown a coherent impact across all key MRI markers associated with disease progression and has been successfully tested at the Karolinska Institute’s Academic Specialist Center in Stockholm on a cohort of patients experiencing disability progression in the absence of relapses, due to a concomitant treatment with an efficacious anti-inflammatory drug, to confirm its potential against the progression of disability, which is the key unmet need for MS patients. The company is currently running the first biomarker-based Phase 2 clinical trial against neuropsychiatric syndromes affecting Long-COVID patients. GeNeuro has also entered into a partnership with the National Institute of Neurological Disorders and Stroke (NINDS), launching a preclinical development program of a novel antibody targeting HERV-K Env